Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 19;216(12):1534-1540.
doi: 10.1093/infdis/jix550.

Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy

Caroline C King  1 , Sascha R Ellington  1 , Nicole L Davis  1 , Robert W Coombs  2   3 , Maria Pyra  4   5 , Ting Hong  5 , Nelly Mugo  4   5 , Rena C Patel  3 , Jairam R Lingappa  3   5 , Jared M Baeten  3   4   5 , Athena P Kourtis  1 ; Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams
Collaborators, Affiliations

Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy

Caroline C King et al. J Infect Dis. .

Abstract

Background: Genital human immunodeficiency virus (HIV) RNA shedding can continue despite HIV being undetectable in blood, and can be associated with transmission.

Methods: We included African women on antiretroviral therapy (ART). Linear and generalized linear mixed models were used to compare the magnitude and prevalence of genital shedding, respectively, by time since ART initiation. Multivariable logistic regression with generalized estimating equations was used to assess predictors of genital shedding among women with undetectable plasma viral load (VL).

Results: Among 1114 women, 5.8% of visits with undetectable plasma VL and 23.6% of visits with detectable VL had genital shedding. The proportion of visits with genital shedding decreased with time since ART initiation but the magnitude of shedding remained unchanged when plasma VL was undetectable (P = .032). Prevalence of shedding did not vary by time since ART initiation when plasma VL was detectable (P = .195), though the magnitude of shedding significantly increased (P = .04). Predictors of genital shedding were HIV disease stage, antiretroviral regimen, and genital ulcers or cervical tenderness.

Discussion: In addition to ART, reducing immune activation through prevention and treatment of HIV-related conditions and genital tract infections may decrease the risk of HIV-1 shedding and potential transmission.

Keywords: HIV; antiretroviral; genital shedding; viral load.

PubMed Disclaimer

Comment in

  • Mucosal HIV Shedding During ART.
    Sivro A, McKinnon LR. Sivro A, et al. J Infect Dis. 2017 Dec 19;216(12):1484-1486. doi: 10.1093/infdis/jix551. J Infect Dis. 2017. PMID: 29240894 No abstract available.

References

    1. Cohen MS, Chen YQ, McCauley M et al. ; HPTN 052 Study Team Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505. - PMC - PubMed
    1. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; (7):CD003510. - PubMed
    1. Graham SM, Holte SE, Peshu NM et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501–7. - PubMed
    1. Cu-Uvin S, DeLong AK, Venkatesh KK et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489–97. - PubMed
    1. John GC, Nduati RW, Mbori-Ngacha DA et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206–12. - PubMed

Publication types

Substances